Few cases of immunoallergic tubulointerstitial nephritis associated with tyrosine kinase inhibitors have been described. We describe the first report case associated with vandetanib, a tyrosine kinase inhibitor indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (CMT) in patients with locally advanced or metastatic non-resectable disease.
Keywords: Allergic acute tubulointerstitial nephritis; Medullary thyroid carcinoma; Tyrosine kinase inhibitor; Vandetanib.